Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

• Status: Terminated
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborator: Genentech, Inc.
• Treatments: Antibodies, Monoclonal; Rituximab

Criteria

Inclusion Criteria:

• Patients with biopsy-proven non-hodgkins lymphoma of follicular grade 1, 2, or 3

• Meeting FLIPI criteria for intermediate or high risk.

• No prior chemotherapy, radiotherapy or immunotherapy for lymphoma;

• Patients may not have known HIV infection, and must not be Hepatitis B Surface Antigen positive.

Exclusion Criteria:

• May not be pregnant or breastfeeding, have documented CNS (Central Nervous System) disease, G-CSF (Granulocyte Colony Stimulating Facto) or GM-CSF (Granulocyte/Macrophage Colony Stimulating Factor) within 2 weeks prior